Effect of IVIg on the in vivo antigen-specific B-cell response. Anti-OVA IgG titers were measured in the serum of OVA-immunized mice treated (n = 7) or not (n = 7) with IVIg, 28 days after the first immunization. The results were compared using the Wilcoxon-Mann-Whitney 2-sample rank-sum test. The median values in the IVIg-treated and control groups were 62 424 and 119 258, respectively. The analysis confirmed that IVIg treatment resulted in significantly lower OVA-specific antibody titers compared with the control group (Mann-Whitney U = 14, n1 = n2 = 7, α = 0.05). The anti–human IgG response was also determined in a similar ELISA, using IVIg instead of OVA as capture antigen and revealed the absence of a significant anti–human IgG response in all mice treated with IVIg at the dilutions tested (titers < 1000).
